Literature DB >> 35661086

Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells.

Xiaoyu Li1, Charos Omonova Tuychi Qizi1, Amari Mohamed Khamis1, Can Zhang2, Zhigui Su3.   

Abstract

Immune cells stand as a critical component of the immune system to maintain the internal environment homeostasis. The dysfunction of immune cells can result in various life-threatening diseases, including refractory infection, diabetes, cardiovascular disease, and cancer. Therefore, strategies to standardize or even enhance the function of immune cells are critical. Recently, nanotechnology has been highly researched and extensively applied for enhancing the cytoplasmic delivery of bioactive molecules to immune cells, providing efficient approaches to correct in vivo and in vitro dysfunction of immune cells. This review focuses on the technologies and challenges involved in improving endo-lysosomal escape, cytoplasmic release and organelle targeted delivery of different bioactive molecules in immune cells. Furthermore, it will elaborate on the broader vision of applying nanotechnology for treating immune cell-related diseases and constructing immune therapies and cytopharmaceuticals as potential treatments for diseases.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  bioactive molecules; cytoplasmic and organelle delivery; immune cells; nanotechnology

Mesh:

Year:  2022        PMID: 35661086     DOI: 10.1007/s11095-022-03284-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  128 in total

Review 1.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 2.  Nanomaterials for T-cell cancer immunotherapy.

Authors:  Ningqiang Gong; Neil C Sheppard; Margaret M Billingsley; Carl H June; Michael J Mitchell
Journal:  Nat Nanotechnol       Date:  2021-01-12       Impact factor: 39.213

Review 3.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 5.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cell       Date:  2018-10-04       Impact factor: 41.582

Review 6.  Engineering dendritic cell vaccines to improve cancer immunotherapy.

Authors:  Caleb R Perez; Michele De Palma
Journal:  Nat Commun       Date:  2019-11-27       Impact factor: 14.919

Review 7.  Immune-based therapies in cardiovascular and metabolic diseases: past, present and future.

Authors:  Andrew J Murphy; Mark A Febbraio
Journal:  Nat Rev Immunol       Date:  2021-07-20       Impact factor: 53.106

Review 8.  The evolution of commercial drug delivery technologies.

Authors:  Ava M Vargason; Aaron C Anselmo; Samir Mitragotri
Journal:  Nat Biomed Eng       Date:  2021-04-01       Impact factor: 25.671

Review 9.  Tolerising cellular therapies: what is their promise for autoimmune disease?

Authors:  Chijioke H Mosanya; John D Isaacs
Journal:  Ann Rheum Dis       Date:  2018-11-02       Impact factor: 19.103

View more
  1 in total

1.  Editorial of Special Issue "Cytoplasmic Delivery of Bioactives".

Authors:  Zimei Wu
Journal:  Pharm Res       Date:  2022-05-23       Impact factor: 4.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.